An interventional study of TMS in Insomnia, Chronic Insomnia and Chronic Insomnia Disorder, sponsored by San Francisco Neurology and Sleep Center. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by San Francisco Neurology and Sleep Center · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 907 studies in Sleep Initiation and Maintenance Disorders with a site in United States — 149 open to participants now, 186 under way, 5 of them phase 3. Sleep Initiation and Maintenance Disorders · United States.
Among the 907 studies in Sleep Initiation and Maintenance Disorders with a site in United States, this one is the 384th largest by planned enrollment of the 858 interventional ones that give a count, is one of 61 that started in 2026, is one of 580 with no phase, reaches primary completion later than 150 of the 185 other live ones, and was the 867th registered.
2,738 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 735 are open to participants now.
Browse Sleep Initiation and Maintenance Disorders studies →149 of the 907 studies in Sleep Initiation and Maintenance Disorders with a site in United States are open now. Recruiting first, the newest first:
Olly, PBC · Sites in United States
Ages 4–16 · Healthy volunteers
Indiana University · Sites in United States
Ages 18+ · Healthy volunteers
Spectrum Clinical Research, LLC · Sites in United States
Ages 45–65 · Women only
Florida State University · Sites in United States
Ages 6–13 · Healthy volunteers
University of Pittsburgh · Sites in United States
Ages 65+ · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 394 Sleep Initiation and Maintenance Disorders studies recruiting now, 156 (40%) set no upper age limit and 208 (53%) stop at 75 or younger; 61 take children under 18; 112 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
907 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 40 · Phase 2 103 · Phase 3 77 · Phase 4 78
First in 1997; this study’s year is marked. 61 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 70 is close to the median of 68 across 2,363 interventional studies indexed under Sleep Initiation and Maintenance Disorders.
Median enrollment 60 across the 858 interventional studies, 68 across the 49 observational. Of the 661 that completed or were terminated, 243 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
187 of 907 have an industry lead sponsor. The 10 most frequent:
San Francisco Neurology and Sleep Center is the lead sponsor of 3 studies on the registry; 3 are open to participants now.
San Francisco Neurology and Sleep Center has 1 study filed under Sleep Initiation and Maintenance Disorders — fewer than ten, so there is no comparison to draw.
80 of the studies in Sleep Initiation and Maintenance Disorders with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06568367Phase 3Axsome Therapeutics, Inc.Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN) | 2026-12 |
| NCT06655883Phase 3Merck Sharp & Dohme LLCA Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants With Opioid Use Disorder (MK-4305-098) | 2027-06-24 |
| NCT07336277Phase 3Emory UniversitySleep Quality and the Efficacy of a Multimodal Sleep Pathway in Hospitalized Orthopedic Trauma Patients | 2027-07 |
| NCT06953869Phase 3Vanda PharmaceuticalsEvaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia | 2027-11 |
| NCT04278404Duke UniversityPharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 2026-11 |
Add all 80 to your calendar (.ics) → With an account.
Among the 907 studies in Sleep Initiation and Maintenance Disorders with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Chronic insomnia disorder is a common condition in which people have ongoing difficulty falling asleep, staying asleep, or waking too early. It affects about 10-12% of adults and can lead to daytime problems, stress, and other health issues. Current treatments include talk therapy (cognitive behavioral therapy for insomnia) and sleep medications, but medications can have side effects and may not work well over the long term.
Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive treatment that uses magnetic pulses applied to the scalp to stimulate specific areas of the brain. It has shown promise in improving sleep quality in people with insomnia by targeting a brain region called the left dorsolateral prefrontal cortex, which plays a role in the overactive brain arousal thought to cause insomnia.
The purpose of this study is to find out whether an accelerated course of rTMS using the EXOMIND™ device can improve sleep in adults with chronic insomnia disorder. The study will enroll approximately 70 participants aged 18 to 85 years at a single site in San Francisco. Participants will receive 6 rTMS sessions (3 times per week for 2 weeks). Each session lasts about 25 minutes.
The study has three phases: a screening phase (up to 25 days) to confirm eligibility using sleep questionnaires and at-home sleep monitoring, a 2-week open-label treatment phase, and a follow-up phase with visits at 1 month and 3 months after the last treatment session. Total participation lasts up to approximately 139 days.
The main goal is to measure whether insomnia severity improves after treatment, using a standard questionnaire called the Insomnia Severity Index (ISI). The study will also measure changes in objective sleep patterns (such as how long it takes to fall asleep, time spent in deep sleep, and total sleep time) recorded by a home sleep monitoring device, as well as changes in sleep quality, stress levels, and overall clinical impression of improvement.
This is an open-label pilot study, meaning all participants will receive the rTMS treatment and there is no placebo group. The study does not involve any medications. Participants must not have certain medical conditions, electronic or metal implants in or near the head, untreated sleep apnea, or active serious psychiatric disorders. Participants who are pregnant or breastfeeding cannot take part.
BACKGROUND AND RATIONALE
Chronic insomnia disorder affects approximately 10-12% of adults worldwide and is associated with increased risk of psychiatric disorders, cardiovascular disease, and reduced quality of life. While cognitive behavioral therapy for insomnia (CBT-I) is the recommended first-line treatment, access remains limited. Pharmacological options carry concerns regarding long-term efficacy, dependency, and adverse effects.
The hyperarousal model of insomnia suggests that excessive activation of arousal systems contributes to the disorder. The left dorsolateral prefrontal cortex (DLPFC) has been identified as a critical node in insomnia pathophysiology, with altered functional connectivity patterns correlating with poor sleep quality and changes in sleep architecture, including increased beta/gamma activity and reduced slow-wave sleep. These findings support the rationale for targeted neuromodulation of this brain region.
Low-frequency repetitive transcranial magnetic stimulation (rTMS) targeting the DLPFC has demonstrated improvements in both subjective sleep quality and objective sleep parameters, with reported response rates of approximately 55% and remission rates of approximately 68%. Protocols using 3-4 sessions per week have shown sustained benefits at 6-12 month follow-up. However, most prior studies have relied primarily on subjective outcome measures with limited polysomnographic or EEG-based sleep data, and optimal stimulation parameters and age-related differences in treatment response remain poorly characterized.
STUDY PROCEDURES
Screening Phase (Day -25 to Day -1):
Screening is conducted in two parts. Part 1 (Day -25 to Day -15) includes a general health assessment, medical history review, vital signs, and subjective sleep evaluation using the Consensus Sleep Diary - Morning Administration (CSD-M) collected over a minimum of 7 consecutive days and the Insomnia Severity Index (ISI). Subjects taking hypnotic medications at the time of consent must complete a minimum 5-day washout before CSD-M and ISI administration. CSD-M data from Part 1 are also used to determine each participant's median habitual bedtime for standardizing subsequent at-home sleep monitoring.
Part 2 (Day -14 to approximately Day -5) includes objective sleep assessment using the Somfit™ home EEG device over 2 consecutive nights. The first night's recording is used to screen for periodic limb movements/restless legs syndrome, sleep-disordered breathing, and parasomnias. Both nights' recordings are used to confirm objective insomnia criteria. Two training sessions for the cognitive test battery and body sway assessments are also completed during Part 2 to reduce learning effects.
For subjects aged 65 years and older, a Mini-Mental State Examination (score ≥25 required) is administered during screening to ensure capacity for safe participation. Motor threshold determination is also performed during screening to calibrate stimulation intensity; the motor threshold is defined as the minimum stimulus intensity required to induce visible contraction of the right thumb.
Open-Label Treatment Phase (Day 1 to approximately Day 14):
The night before the first treatment session, participants complete an at-home Somfit™ sleep recording to establish baseline objective sleep data. On Day 1, pre-treatment assessments are completed, including vital signs, CSD-M, ISI, Pittsburgh Sleep Quality Index (PSQI), Clinical Global Impression - Severity (CGI-S), Patient Global Impression - Severity (PGI-S), and Perceived Stress Scale (PSS).
Treatment consists of 6 rTMS sessions administered 3 times per week over 2 weeks using the EXOMIND™ device (BTL-699-2). Each session delivers 6,300 pulses at alternating frequencies of 12, 15, and 18 Hz, with a total session duration of 24 minutes and 30 seconds. The stimulation target is the left DLPFC, localized using the standard 5.5-cm anterior method. All sessions are conducted at the research site with medical staff present. Blood pressure and heart rate are recorded at the beginning and end of each session, and adverse events are monitored using a standardized checklist derived from existing TMS safety literature.
On the day of the 6th (final) treatment session, post-treatment assessments are completed, including vital signs, CSD-M, PSQI, ISI, CGI-S, CGI - Improvement (CGI-I), PGI-S, PGI - Improvement (PGI-I), and PSS.
Follow-Up Phase:
Participants return for follow-up visits at 1 month and 3 months after the last treatment session. Safety assessments and outcome measures are repeated at each visit. If a participant withdraws prematurely, end-of-study assessments are performed as soon as possible.
OBJECTIVE SLEEP MONITORING
Objective sleep architecture is assessed using the Somfit™ home EEG monitoring device at screening (2 nights), baseline (1 night before Day 1), and at post-treatment and follow-up time points. Parameters recorded include sleep onset latency (SOL), wake after sleep onset (WASO), total sleep time (TST), sleep efficiency (SE), Stage N3 duration, and slow-wave activity (SWA).
AGE GROUP COMPARISON
The study enrolls both adult (18-64 years) and elderly (65-85 years) participants, with approximately equal proportions targeted in each group (neither group exceeding approximately 60% of total enrollment). This design allows exploratory comparison of treatment response across age groups, addressing a gap in the existing literature regarding age-related differences in rTMS efficacy for insomnia.
STATISTICAL APPROACH
Descriptive statistics will summarize demographic and baseline characteristics. The primary analysis will use repeated measures ANOVA to assess changes in outcome scores across four time points (baseline, post-intervention, 1-month follow-up, and 3-month follow-up). Paired t-tests will evaluate within-subject changes in secondary measures between baseline and each post-treatment time point. A p-value of less than 0.05 will be considered statistically significant.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A predominant complaint of dissatisfaction with sleep quantity or quality, associated with one (or more) of the following symptoms:
Difficulty initiating sleep Difficulty maintaining sleep, characterized by frequent awakenings or problems returning to sleep after awakenings Early-morning awakening with inability to return to sleep. The sleep disturbance causes distress or impairment in social, occupational, educational, academic, behavioral, or other important areas of functioning.
The sleep difficulty occurs at least 3 nights per week. The sleep difficulty is present for at least 3 months. The sleep difficulty occurs despite adequate opportunity for sleep. The insomnia is not better explained by and does not occur exclusively during the course of another sleep-wake disorder (eg, narcolepsy, a breathing-related sleep disorder, a circadian rhythm sleep-wake disorder, a parasomnia).
The insomnia is not attributable to the physiological effects of a substance (eg, a drug of abuse, a medication).
Coexisting mental disorders and medical conditions do not adequately explain the predominant complaint of insomnia.
Exclusion Criteria:
Note: Subjects with chronic but stable, well-controlled conditions may be allowed in the study upon agreement with the investigator and the sponsor's Safety Physician.
T interval corrected according to Fridericia's formula: ≥450 msec (males);
≥470 msec (females). Evidence of 2nd and 3rd degree atrioventricular block, or 1st degree atrioventricular block with PR interval >210 msec, left bundle branch block.
Features of new ischemia. Other clinically important arrhythmia. Note: Subjects with right bundle branch block may be allowed provided confirmation that right bundle branch block is not associated with underlying cardiac/lung diseases.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive 6 sessions of repetitive transcranial magnetic stimulation (rTMS) using the EXOMIND™ device (BTL-699-2), administered 3 times per week over 2 weeks. Each session delivers 6,300 magnetic pulses at alternating frequencies of 12, 15, and 18 Hz to the left dorsolateral prefrontal cortex (DLPFC), localized using the standard 5.5-cm anterior method. Total session duration is 24 minutes and 30 seconds. Stimulation intensity is calibrated to each participant's individual motor threshold, defined as the minimum stimulus required to produce visible contraction of the right thumb. All sessions are conducted on-site at the research center with medical staff present. Blood pressure and heart rate are monitored before and after each session.
Device: TMS
The EXOMIND™ (BTL-699-2) is a repetitive transcranial magnetic stimulation (rTMS) device that delivers targeted electromagnetic pulses to cortical brain regions. In this study, stimulation is applied to the left dorsolateral prefrontal cortex (DLPFC), a region implicated in executive function, working memory, and attention. The DLPFC target is localized using the standard 5-cm rule, measured anterior to the motor cortex hot spot. Each treatment session uses a multi-frequency protocol alternating between 12, 15, and 18 Hz stimulation frequencies, delivering a total of 6,300 pulses over 24 minutes and 30 seconds. Stimulation intensity is calibrated to each participant's resting motor threshold, defined as the minimum stimulus intensity required to produce a visible contraction of the right abductor pollicis brevis muscle. Six sessions are administered twice weekly over approximately 3 weeks.
Change From Baseline in Insomnia Severity Index (ISI) Total Score at 1-Month Follow-Up
The Insomnia Severity Index (ISI) is a 7-item self-report questionnaire that assesses the nature, severity, and impact of insomnia. Each item is rated on a 0-4 Likert scale, yielding a total score ranging from 0 to 28. Higher scores indicate greater insomnia severity. Clinical severity categories are: 0-7 (no clinically significant insomnia), 8-14 (subthreshold insomnia), 15-21 (moderate clinical insomnia), and 22-28 (severe clinical insomnia). The primary outcome is the change in ISI total score from baseline (Day 1, pre-treatment) to the 1-month follow-up visit. A negative change indicates improvement.
Time frame: From baseline to the 1-month follow-up
Change From Baseline in Sleep Onset Latency (SOL)
Sleep onset latency (SOL) is defined as the time in minutes from lights off to the first epoch of any sleep stage, as measured by the Somfit™ home EEG recording device. A negative change from baseline indicates faster sleep onset and improvement.
Time frame: Baseline (night before Day 1), day of last rTMS session (approximately Day 21), 1-month follow-up (approximately Day 51), and 3-month follow-up (approximately Day 111)
Change From Baseline in Stage N3 Duration
Stage N3 duration is defined as the total time in minutes spent in N3 (deep/slow-wave) sleep during the recording period, as measured by the Somfit™ home EEG recording device. N3 sleep is the deepest stage of non-REM sleep and is associated with restorative functions. A positive change from baseline indicates an increase in deep sleep and improvement.
Time frame: Baseline (night before Day 1), day of last rTMS session (approximately Day 21), 1-month follow-up (approximately Day 51), and 3-month follow-up (approximately Day 111)
Change From Baseline in Wake After Sleep Onset (WASO)
Wake after sleep onset (WASO) is defined as the total time in minutes spent awake after initial sleep onset until the final awakening, as measured by the Somfit™ home EEG recording device. A negative change from baseline indicates less nighttime wakefulness and improvement.
Time frame: Baseline (night before Day 1), day of last rTMS session (approximately Day 21), 1-month follow-up (approximately Day 51), and 3-month follow-up (approximately Day 111)
Change From Baseline in Total Sleep Time (TST)
Total sleep time (TST) is defined as the total time in minutes spent in any sleep stage (N1, N2, N3, and REM) during the recording period, as measured by the Somfit™ home EEG recording device. A positive change from baseline indicates more sleep and improvement.
Time frame: Baseline (night before Day 1), day of last rTMS session (approximately Day 21), 1-month follow-up (approximately Day 51), and 3-month follow-up (approximately Day 111)
Change From Baseline in Sleep Efficiency (SE)
Sleep efficiency (SE) is defined as the percentage of total time in bed spent asleep, calculated as (total sleep time / total time in bed) × 100, as measured by the Somfit™ home EEG recording device. A positive change from baseline indicates improved sleep efficiency.
Time frame: Baseline (night before Day 1), day of last rTMS session (approximately Day 21), 1-month follow-up (approximately Day 51), and 3-month follow-up (approximately Day 111)
Change From Baseline in Slow-Wave Activity (SWA)
Slow-wave activity (SWA) is defined as the EEG spectral power in the low-frequency range (typically 0.5-4.0 Hz) during non-REM sleep, as measured by the Somfit™ home EEG recording device. SWA is a quantitative marker of sleep depth and homeostatic sleep pressure. A positive change from baseline indicates enhanced deep sleep intensity and improvement.
Time frame: Baseline (night before Day 1), day of last rTMS session (approximately Day 21), 1-month follow-up (approximately Day 51), and 3-month follow-up (approximately Day 111)
Change From Baseline in Insomnia Severity Index (ISI) Total Score at Day 21 and 3-Month Follow-Up
The Insomnia Severity Index (ISI) is a 7-item self-report questionnaire that assesses the nature, severity, and impact of insomnia. Each item is rated on a 0-4 Likert scale, yielding a total score ranging from 0 to 28. Higher scores indicate greater insomnia severity. Clinical severity categories are: 0-7 (no clinically significant insomnia), 8-14 (subthreshold insomnia), 15-21 (moderate clinical insomnia), and 22-28 (severe clinical insomnia). This secondary outcome captures the change in ISI total score from baseline to the day of the last rTMS session and to the 3-month follow-up visit. A negative change indicates improvement. The 1-month follow-up ISI assessment is captured separately as the primary outcome measure.
Time frame: Baseline (Day 1, pre-treatment), day of last rTMS session (approximately Day 21), and 3-month follow-up (approximately Day 111)
Change From Baseline in Subjective Sleep Parameters as Measured by the Consensus Sleep Diary - Morning Administration (CSD-M)
The Consensus Sleep Diary - Morning Administration (CSD-M) is a standardized self-report instrument completed each morning to capture subjective sleep parameters from the prior night. Key parameters include subjective sleep onset latency (sSOL), subjective wake after sleep onset (sWASO), subjective total sleep time (sTST), time in bed, subjective sleep efficiency, number of awakenings, and subjective sleep quality rating. Changes from baseline in these diary-derived parameters will be assessed. Improvements are indicated by decreased sSOL and sWASO, increased sTST and sleep efficiency, and higher sleep quality ratings.
Time frame: Baseline (Day 1, pre-treatment), day of last rTMS session (approximately Day 21), 1-month follow-up (approximately Day 51), and 3-month follow-up (approximately Day 111)
Change From Baseline in Sleep Quality as Measured by the Pittsburgh Sleep Quality Index (PSQI)
The Pittsburgh Sleep Quality Index (PSQI) is a 19-item self-report questionnaire that assesses sleep quality and disturbances over the preceding one-month period. It yields seven component scores (subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction), each scored from 0 to 3. The seven component scores are summed to produce a global PSQI score ranging from 0 to 21. A global score greater than 5 indicates poor sleep quality. A negative change from baseline indicates improvement in sleep quality.
Time frame: Baseline (Day 1, pre-treatment), day of last rTMS session (approximately Day 21), 1-month follow-up (approximately Day 51), and 3-month follow-up (approximately Day 111)
Patient Global Impression - Improvement (PGI-I)
The Patient Global Impression - Improvement (PGI-I) is a single-item self-report measure in which the subject rates the overall change in their insomnia since the start of the study on a 7-point Likert scale ranging from 1 (very much improved) to 7 (very much worse), with 4 indicating no change. Lower scores indicate greater perceived improvement. As this is a post-baseline measure of change, there is no baseline value; scores are assessed at each post-treatment time point.
Time frame: Day of last rTMS session (approximately Day 21), 1-month follow-up (approximately Day 51), and 3-month follow-up (approximately Day 111)
Change From Baseline in Patient Global Impression - Severity (PGI-S)
The Patient Global Impression - Severity (PGI-S) is a single-item self-report measure in which the subject rates the current severity of their insomnia on a 7-point Likert scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill). A negative change from baseline indicates the subject perceives a reduction in insomnia severity and improvement.
Time frame: Baseline (Day 1, pre-treatment), day of last rTMS session (approximately Day 21), 1-month follow-up (approximately Day 51), and 3-month follow-up (approximately Day 111)
Change From Baseline in Clinical Global Impression - Severity (CGI-S)
The Clinical Global Impression - Severity (CGI-S) is a single-item clinician-rated measure in which the investigator rates the current severity of the subject's insomnia on a 7-point Likert scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill). The rating is based on the clinician's total clinical experience with the insomnia population. A negative change from baseline indicates the clinician perceives a reduction in insomnia severity and improvement.
Time frame: Baseline (Day 1, pre-treatment), day of last rTMS session (approximately Day 21), 1-month follow-up (approximately Day 51), and 3-month follow-up (approximately Day 111)
Clinical Global Impression - Improvement (CGI-I)
The Clinical Global Impression - Improvement (CGI-I) is a single-item clinician-rated measure in which the investigator rates the overall change in the subject's insomnia since the start of the study on a 7-point Likert scale ranging from 1 (very much improved) to 7 (very much worse), with 4 indicating no change. Lower scores indicate greater clinician-assessed improvement. As this is a post-baseline measure of change, there is no baseline value; scores are assessed at each post-treatment time point.
Time frame: Day of last rTMS session (approximately Day 21), 1-month follow-up (approximately Day 51), and 3-month follow-up (approximately Day 111)
Change From Baseline in Perceived Stress Level as Measured by the Perceived Stress Scale (PSS)
The Perceived Stress Scale (PSS) is a 10-item self-report questionnaire that measures the degree to which situations in a respondent's life are appraised as stressful over the preceding one-month period. Each item is rated on a 5-point Likert scale ranging from 0 (never) to 4 (very often). Total scores range from 0 to 40, with higher scores indicating greater perceived stress. Score categories are: 0-13 (low stress), 14-26 (moderate stress), and 27-40 (high perceived stress). Elevated perceived stress has been associated with insomnia severity and may serve as a mediator of treatment response. A negative change from baseline indicates a reduction in perceived stress and improvement.
Time frame: Baseline (Day 1, pre-treatment), day of last rTMS session (approximately Day 21), 1-month follow-up (approximately Day 51), and 3-month follow-up (approximately Day 111)
Plan to share: Undecided
Started Aug 2026 (actual). Primary completion is estimated for Aug 2028, 23 months after the start.
Of 1,219 non-industry interventional studies with no phase under Sleep Initiation and Maintenance Disorders, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 35. This study's planned 23 months is above that.
Counting every sponsor, half of 1,297 studies reached it within 15 months; a quarter within 6 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sleep Initiation and Maintenance Disorders →
San Francisco Neurology and Sleep Center